British government funding groups are looking for startups that will sustain the resurgence in the country's economy. And that means more money for bioinformatics businesses, with the Technology Strategy Board accepting applications for new funding from next month.
The parents of a teenage boy who died of glioblastoma multiforme are trying to build a database of 50,000 human genomes.
Last month Pfizer and the Broad Institute published details of their work to find diabetes drug targets in genome data. Now Pfizer has teamed with Merck KGaA to give the institute another pot of cash to investigate lupus.
Duke is setting up an applied genomics and precision medicine center as part of the reshuffle.
The expansion of whole-genome sequencing into clinical care has intensified discussions about the limitations of the technology. Illumina CEO Jay Flatley this week acknowledged sequencing still has some weaknesses and identified what he sees as the solution--improved bioinformatics.
Rheumatoid arthritis has become a key therapeutic area for Johnson & Johnson, with Remicade and Simponi generating sales of $7.6 billion by treating the disease and other autoimmune disorders last year. To maintain its position, J&J subsidiary Janssen is working with the San Diego Supercomputer Center on whole genome sequence analysis.
Google's expansions into life sciences and genomics have raised two big, as yet unanswered, questions--how will they affect the industry, and what do they mean for the company? This week, the San Francisco Chronicle looked into possible answers to both questions.
When IBM was preparing its artificial-intelligence program Watson to compete on the game show "Jeopardy!," it made the system read Wikipedia. The training worked and Watson beat its human competitors. Now IBM and the New York Genome Center are testing whether making Watson read PubMed can help defeat cancer.
A genomics data-sharing nonprofit is trying to raise $25,000 on the crowdfunding site indiegogo. The organization, DNAdigest, runs workshops, hackathons and public education programs designed to promote the sharing of genetic data.
While budget constraints at NIH have put the squeeze on researchers, the growing potential of genome sequencing offers it some protection from cutbacks. However, fluctuations in federal funding awards can affect all sectors. Such a shift in spending has put 22 jobs at the Broad Institute under threat.